Tesamorelin and post: how long after eating can I give the injection?

Tesamorelin is usually recommended to be taken on a relatively empty stomach, and many therapeutic protocols suggest waiting about 1.5 to 2 hours after eating before administering tesamorelin injections to support natural growth hormone signaling [1-4]. Although most clinical studies have focused primarily on dosing rather than precise meal timing, the topic of „tesamorelin and fasting” is often discussed, as fasting conditions are generally preferred—high insulin and blood sugar levels can temporarily suppress the body's natural growth hormone secretion.

Tesamorelin works by mimicking growth hormone-releasing hormone (GHRH), a natural hormone that signals the pituitary gland to release endogenous growth hormone (GH), which is GH naturally produced by the body [1,2]. As GH levels increase, insulin-like growth factor-1 (IGF-1) levels also increase. In normal physiology, growth hormone secretion tends to increase during fasting and decrease after meals, especially those rich in carbohydrates or sugar. For this reason, many clinicians recommend taking tesamorelin when insulin levels are lower, such as at bedtime or a few hours after the last meal of the day.

Clinical trials evaluating tesamorelin in the context of HIV-associated lipodystrophy and fatty liver disease have consistently used a once-daily dosing regimen, but have typically not mandated strict meal timing [3–6]. Nevertheless, because glucose and insulin can inhibit GH secretion, clinical practice often recommends fasting prior to tesamorelin administration to potentially enhance hormonal response.

Many therapeutic protocols also recommend avoiding food for about 30 to 60 minutes after tesamorelin injection. The goal of this recommendation is to allow the tesamorelin-stimulated GH release to occur before insulin levels rise again after a meal. Although direct studies comparing meal timing are limited, fasting administration remains a common approach with GHRH analogs like tesamorelin.

Tesamorelin generally demonstrated stable blood glucose control in clinical trials, despite increasing GH–IGF-1 pathway activity. In studies by Falutz J et al. (2007, 2010), tesamorelin significantly reduced visceral fat without causing a notable worsening of fasting glucose or HbA1c in most participants [3,4]. HbA1c is a long-term marker used to assess average blood glucose levels over several months. Similarly, Stanley TL et al. (2019) observed no significant differences in fasting glucose or HbA1c compared to placebo during long-term tesamorelin treatment [5].

Generally speaking, while specific fasting recommendations can vary, tesamorelin is often administered approximately 1.5 to 2 hours after a meal, and many individuals wait at least 30 minutes post-injection before consuming food again to support more natural growth hormone secretion patterns [1–5].

Where to inject Tesamorelin and how to administer it correctly?

Tesamorelin is administered as a subcutaneous injection, most commonly in the abdominal area, and injection sites are typically rotated regularly to help minimize irritation and local skin reactions [1-4]. Subcutaneous injection means the drug is given into the fatty tissue directly under the skin, rather than directly into the muscle. Clinical trials have consistently used daily subcutaneous injections into the abdominal area as the standard method of tesamorelin administration.

Tesamorelin is usually supplied as a lyophilized powder, meaning it has been freeze-dried for increased stability and must be reconstituted with sterile or bacteriostatic water before use [1,2]. After reconstitution, the prescribed dose is drawn into an insulin syringe and injected subcutaneously.

The abdomen is the preferred injection site for most studies and therapeutic protocols. Injections are generally recommended in the abdominal area, avoiding the immediate vicinity of the navel, scar tissue, bruised skin, irritated skin, or areas with active reactions [1–3]. Daily rotation of injection sites can help reduce the risk of redness, swelling, discomfort, bruising, or itching, which are among the most commonly reported injection site reactions in clinical studies.

The typical serving process usually involves the following steps:

• Dissolve the tesamorelin powder using the provided diluent or bacteriostatic water as per the product instructions.
• Gently swirl the vial until the solution becomes clear. Vigorous shaking is usually avoided as peptides can be sensitive to over-mixing.
• Draw the prescribed dose into the syringe.
• Clean the selected injection site on the abdomen with an alcohol swab.
• Pinch a fold of skin and insert the needle subcutaneously at approximately a 90-degree angle.
• Inject the medication slowly and evenly.
• Remove the needle and safely dispose of the syringe in the appropriate medical waste container.

Clinical trials by Falutz J et al. (2010) and Stanley TL et al. (2014) used daily subcutaneous injections of 2 mg tesamorelin to reduce visceral abdominal fat and liver fat in HIV-positive individuals [3,4]. Similar injection methods were also used in long-term metabolic and NAFLD studies [5,6].

Reactions at the injection site are among the most frequently reported adverse events of tesamorelin. In clinical trials, some participants experienced mild redness, itching, swelling, bruising, or discomfort at the administration site, although serious injection-related complications were rare [3–6].

Generally speaking, tesamorelin is administered via daily subcutaneous injections into the abdominal area, using proper sterile technique and regularly rotating injection sites to improve comfort and limit local irritation.

Disclaimer

The content is for educational and scientific information purposes only and should not be interpreted as medical advice, diagnosis, or treatment recommendation. Tesamorelin is a prescription medication that requires medical supervision. Meal timing, fasting practices, and dosing schedules should be individualized by a qualified healthcare professional. Tesamorelin should be prepared and administered only under the supervision of a qualified healthcare professional. Incorrect injection technique or unsupervised peptide use may increase the risk of adverse events or complications.

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available at: NCBI Bookshelf: Tesamorelin Overview
2. PubChem. (2025). Tesamorelin Compound Summary. National Center for Biotechnology Information. Available at: PubChem Tesamorelin Summary
3. Falutz J, Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
4. Stanley TL, Feldpausch, M. N., Oh, J., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
5. Stanley TL, Fourman, L. T., Feldpausch, M. N., et al. (2019). Effect of tesamorelin on nonalcoholic fatty liver disease in HIV-positive individuals: A randomized, double-blind, multicenter study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
6. Falutz J, Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058